You are here

Dynamic combinatorial chemistry for nucleic acids

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41GM079897-01
Agency Tracking Number: GM079897
Amount: $102,750.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: 2007
Award Year: 2007
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
FIREBIRD BIOMOLECULAR SCIENCES, LLC PO BOX 13983
GAINESVILLE, FL 32641
United States
DUNS: 192849011
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 STEVEN BENNER
 (352) 271-7005
 sbenner@ffame.org
Business Contact
Phone: (352) 219-3570
Email: rhughes@firebirdbio.com
Research Institution
 FOUNDATION FOR APPLIED MOLECUL
 
FOUNDATION FOR APPLIED MOLEC EVOLUTION, INC. PO Box 13174
GAINESVILLE, FL 32604 2194
United States

 Domestic Nonprofit Research Organization
Abstract

DESCRIPTION (provided by applicant): The proposed research will develop dynamic combinatorial chemistry as a new and innovative strategy to allow a DNA or RNA target in a biological sample to assemble its own template under conditions of dynamic equilibrium. This chemistry incorporates element that allows the template-created primer to primes the synthesis of a strand of DNA complementary to the target. The selectivity of the process is such that a single DNA sequence in a genome as complex as the human genome can be targeted. The architecture of the process, however, allows it to discriminate against single nucleotide changes with the effectiveness of small duplexes. Consistent with the basic research/business mission/plan of the Foundation for Applied Molecular Evolution and Firebird Biomolecular ("We do not make DNA assays. We develop chemistry that makes DNA assays better"), this will create a platform technology that meets specifications that are unavailable at the present time: selectivity of a probe as if it were a long oligonucleotide, but discrimination by the probe as if it were a short oligonucleotide. This platform technology should have application in many assays, including in human diagnostics and research markets. In preliminary studies, a proof of concept showed that this combinatorial chemistry architecture met the novel specifications when the target was DNA. The Phase 1 milestone will be passed if similar success can be obtained with RNA as a target. Potential commercial applications in human medicine are substantial, starting with applications in biomedical research, where these tools will allow us to detect messenger RNA, RNAi, and other RNA molecules important in biology. Several important diagnostics and drug development tools been driven in the past decade through the creation of platform chemical technologies by scientists at the Foundation for Applied Molecular Evolution. Such technologies have commercial impact far beyond their development costs because they deliver a set of chemical performance specifications that is unavailable by existing chemistry. The proposed work will develop another platform technology, this one allowing the detection of nucleic acid targets through a novel combination of dynamic combinatorial chemistry, enzymology, and nucleic acid science.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government